Digital twins in biomedicine
TechCrunch reports on Mantis Biotech’s work to generate digital twins—synthetic representations of human anatomy, physiology, and behavior. The aim is to create rich, diverse datasets that can be used to address data availability gaps in medicine, enabling researchers to test hypotheses, validate models, and simulate patient-specific trajectories without exposing real-world patient data. This approach could reduce data access friction, increase reproducibility, and unlock insights that are hard to achieve with limited datasets.
Yet the concept raises questions about data fidelity, representation bias, and the ethical implications of synthetic analogs. Ensuring that digital twins accurately reflect diverse patient populations is critical to avoid biased conclusions. Additionally, the governance and validation of synthetic data pipelines will be essential to establish trust with regulators, clinicians, and payers. As with any biomedical AI effort, there is a delicate balance between accelerating discovery and maintaining rigorous oversight of model risk, privacy, and consent considerations.
From a market perspective, digital twins could become a staple in preclinical research, precision medicine, and regulatory science. Companies building synthetic datasets and simulation platforms stand to gain a competitive edge by enabling faster experimentation cycles and more robust modeling. Investors will watch for evidence of clinical translation, data stewardship policies, and partnerships with research institutions that can demonstrate real-world value and ethical stewardship.
Bottom line: Digital twins in biomedicine are an intriguing frontier with the potential to transform data access and experimentation in healthcare, while requiring careful governance to manage bias, privacy, and clinical validity concerns.